PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Nanoparticle therapy offers new hope for prostate cancer patients

Nanoparticle therapy offers new hope for prostate cancer patients
2024-10-16
(Press-News.org) Prostate cancer is the second leading cause of cancer death among American men. 

A ground-breaking study, conducted by researchers from the University of Virginia, Mount Sinai, the University of Michigan, the University of Texas and others, has demonstrated the clinical success of a new nanoparticle-based, laser-guided therapy for prostate cancer treatment. 

The study, which involved 44 men with localized prostate cancer, used gold nanoshellss in combination with magnetic resonance imaging (MRI) and ultrasound fusion — an advanced technique that enhances MRI data — to precisely target and eliminate cancerous prostate tissue. 

Gold nanoshells are tiny particles, thousands of times smaller than a human hair, that can be engineered to strongly absorb specific wavelengths of light and generate heat. In this case, gold nanoshells were designed to accumulate in the tumors, allowing for highly targeted near-infrared laser treatment that heats and destroys the cancerous tissue while sparing surrounding healthy cells.

This innovative method, called nanoparticle-directed focal photothermal ablation, successfully eliminated cancerous cells in 73% of patients after 12 months, as confirmed by negative biopsies in the treated areas. Importantly, the treatment was able to achieve these results while preserving key functions, including urinary and sexual health, and without observed side effects, marking a significant improvement in the quality of life for patients.

"Our findings represent a major step forward in prostate cancer treatment. This therapy not only effectively eliminates cancerous cells but also preserves key quality-of-life factors, which is a huge win for patients," said Jennifer L. West, Ph.D., Dean of the School of Engineering and Applied Science at the University of Virginia, an author on this paper and inventor of this technology. 

"This study showcases the strength of interdisciplinary collaboration,” West continued. “Together, we’re pushing the boundaries of what's possible in cancer treatment, and it's exciting to be at the forefront of this innovation."

This new cancer treatment is being commercialized by Nanospectra Biosciences, Inc., a company co-founded by Dean West.

 

A Multi-Institutional Study of Magnetic Resonance/Ultrasound Fusion–Guided Nanoparticle-Directed Focal Therapy for Prostate Ablation was published online September 3, 2024, in the Journal of Urology.

About UVA Engineering: As part of the top-ranked, comprehensive University of Virginia, UVA Engineering is one of the nation’s oldest and most respected engineering schools. Our mission is to make the world a better place by creating and disseminating knowledge and by preparing future engineering leaders. Outstanding students and faculty from around the world choose UVA Engineering because of our growing and internationally recognized education and research programs. UVA is the No. 1 public engineering school in the country for the percentage of women graduates, among schools with at least 75 degree earners; among the top engineering schools in the United States for the four-year graduation rate of undergraduate students; and among the top-growing public engineering schools in the country for the rate of Ph.D. enrollment growth. Our research program has grown by 95% since 2016. Learn more at engineering.virginia.edu.

END

[Attachments] See images for this press release:
Nanoparticle therapy offers new hope for prostate cancer patients Nanoparticle therapy offers new hope for prostate cancer patients 2

ELSE PRESS RELEASES FROM THIS DATE:

UVA researchers engineer AI breakthrough in human action detection technology

UVA researchers engineer AI breakthrough in human action detection technology
2024-10-16
What if a security camera could not only capture video but understand what’s happening — distinguishing between routine activities and potentially dangerous behavior in real time? That’s the future being shaped by researchers at the University of Virginia’s School of Engineering and Applied Science with their latest breakthrough: an AI-driven intelligent video analyzer capable of detecting human actions in video footage with unprecedented precision and intelligence. The system, called the Semantic and Motion-Aware Spatiotemporal Transformer Network (SMAST), promises a wide range of ...

Bolstering the fight against antibiotic-resistant bacteria

2024-10-16
GAINESVILLE, Fla. — University of Florida Health scientists exploring how combinations of antibiotics can fight resistant bacteria have been awarded an $11.8 million grant for work that could help save the tens of thousands of lives lost yearly to infections that are increasingly plaguing humanity. The National Institutes of Health, or NIH, grant to the UF College of Medicine and the UF College of Pharmacy will support scientists working to uncover the mechanics of how bacteria and antibiotics interact, down to the molecular level. That mechanistic knowledge ...

Deep learning illuminates atmospheric blocking events of past, future

Deep learning illuminates atmospheric blocking events of past, future
2024-10-16
Atmospheric blocking events are persistent, high-impact weather patterns that occur when large-scale high-pressure systems become stationary and divert the jet stream and storm tracks for days to weeks, and can be associated with record-breaking flooding or heat waves, such as in Europe in 2023. In a new study, University of Hawai‘i at Mānoa atmospheric scientist Christina Karamperidou used a deep learning model to infer the frequency of blocking events over the past 1,000 years and shed light on how future climate change may impact these significant phenomena.    “This study set out to extract a paleoweather signal from ...

Kidney transplantation among those with HIV infections shown safe and effective

2024-10-16
It is just as safe and effective for people with HIV in need of kidney transplantation to get their organ from donors who are also HIV positive as it is from donors who are not infected with the virus, a new study shows. Survival rates for organ recipients one and three years after the procedure were the same for donors with or without HIV. Also the same were risks of serious side effects, such as infection, fever, and rejection in the donated organ. In what is the largest comparative trial of the experimental procedures since the first transplant was performed in the United States in 2016, researchers ...

Longer-term data from SWOG S1826 trial confirm nivolumab-AVD benefit in Hodgkin lymphoma

2024-10-16
In mid-2023, the SWOG S1826 phase 3 trial in advanced Hodgkin lymphoma reported highly positive primary results earlier than expected, after the trial’s second planned interim analysis found the preset threshold for efficacy had already been reached.  Now, a follow-up analysis with additional data – a median follow-up of 2.1 years – confirms the durability of those initial findings: among the 970 newly diagnosed adolescents and adults randomized to the trial, those who received a combination of nivolumab plus AVD chemotherapy (N-AVD) had a significantly lower risk of cancer progression ...

In landmark study, immunotherapy boosts survival of advanced Hodgkin lymphoma

2024-10-16
A treatment that rallies the immune system to destroy cancer raised the survival rate for advanced Hodgkin lymphoma patients to a remarkable 92 percent, suggesting a new standard therapy for the disease. The New England Journal of Medicine published the innovative clinical trial results this week. Young people are most at risk to get Hodgkin lymphoma, an uncommon blood and immune system cancer that falls within the general category of lymphomas. With this new treatment, scientists believe they ...

Kidney transplantation between donors and recipients with HIV is safe

Kidney transplantation between donors and recipients with HIV is safe
2024-10-16
WHAT:  Kidney transplantation from deceased donors with HIV (HIV D+) to recipients with HIV (HIV R+) was safe and comparable to kidney transplantation from donors without HIV (HIV D-) in a multicenter observational study in the United States. The clinical outcomes observed were consistent with smaller pilot studies, but this National Institutes of Health (NIH)-funded clinical trial was the first statistically powered to demonstrate noninferiority, which means that an approach being studied is as good as standard clinical practice. The results were published today ...

Brown researchers show how gut hormones control aging in flies and how it relates to human biology

Brown researchers show how gut hormones control aging in flies and how it relates to human biology
2024-10-16
PROVIDENCE, R.I. [Brown University] — Biologists at Brown University have discovered how a neuropeptide hormone made in the gut of flies can control their lifespan. The findings, published in PNAS, have implications for humans, too, the researchers say — especially as new diabetes and obesity medications based on gut hormones in the same family of the fly hormone are becoming more widespread. For the past two decades, study author Marc Tatar, a professor of biology affiliated with the Center on the Biology of Aging at Brown University, has studied how the hormones insulin and insulin-like ...

Which clot-busting drug is tied to better recovery after stroke?

2024-10-16
EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, WEDNESDAY, OCTOBER 16, 2024 MINNEAPOLIS – For people with ischemic stroke, treatment with the clot-busting drug tenecteplase is associated with a slightly higher likelihood of an excellent recovery and reduced disability three months later than the drug alteplase, according to a meta-analysis published in the October 16, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology. Researchers found that the likelihood of good recovery was similar ...

Study: breast cancer drug shows potential for rare appendix cancer

Study: breast cancer drug shows potential for rare appendix cancer
2024-10-16
Researchers at University of California San Diego School of Medicine found an FDA-approved drug used to treat breast cancer has the potential to be an effective therapeutic for a specific type of appendix cancer.  The clinical trial results, publishing in the October 16, 2024 online edition of the Journal of Clinical Oncology, showed the oral medication, known as palbociclib, stabilized tumor growth and reduced blood tumor marker levels in patients with peritoneal mucinous carcinomatosis (PMC). This form of cancer originates in the appendix and is often resistant to standard chemotherapy. “Finding that a breast cancer drug is ...

LAST 30 PRESS RELEASES:

‘Molecular shield’ placed in the nose may soon treat common hay fever trigger

Beetles under climate stress lay larger male eggs: Wolbachia infection drives adaptive reproduction strategy in response to rising temperature and CO₂

Groundbreaking quantum study puts wave-particle duality to work

Weekly injection could be life changing for Parkinson’s patients

Toxic metals linked to impaired growth in infants in Guatemala

Being consistently physically active in adulthood linked to 30–40% lower risk of death

Nerve pain drug gabapentin linked to increased dementia, cognitive impairment risks

Children’s social care involvement common to nearly third of UK mums who died during perinatal period

‘Support, not judgement’: Study explores links between children’s social care involvement and maternal deaths

Ethnic minority and poorer children more likely to die in intensive care

Major progress in fertility preservation after treatment for cancer of the lymphatic system

Fewer complications after additional ultrasound in pregnant women who feel less fetal movement

Environmental impact of common pesticides seriously underestimated

The Milky Way could be teeming with more satellite galaxies than previously thought

New study reveals surprising reproductive secrets of a cricket-hunting parasitoid fly

Media Tip Sheet: Symposia at ESA2025

NSF CAREER Award will power UVA engineer’s research to improve drug purification

Tiny parasitoid flies show how early-life competition shapes adult success

New coating for glass promises energy-saving windows

Green spaces boost children’s cognitive skills and strengthen family well-being

Ancient trees dying faster than expected in Eastern Oregon

Study findings help hone precision of proven CVD risk tool

Most patients with advanced melanoma who received pre-surgical immunotherapy remain alive and disease free four years later

Introducing BioEmu: A generative AI Model that enables high-speed and accurate prediction of protein structural ensembles

Replacing mutated microglia with healthy microglia halts progression of genetic neurological disease in mice and humans

New research shows how tropical plants manage rival insect tenants by giving them separate ‘flats’

Condo-style living helps keep the peace inside these ant plants

Climate change action could dramatically limit rising UK heatwave deaths

Annual heat-related deaths projected to increase significantly due to climate and population change

Researchers discover new way cells protect themselves from damage

[Press-News.org] Nanoparticle therapy offers new hope for prostate cancer patients